Wikisage, the free encyclopedia of the second generation, is digital heritage
Lennox-Gastaut syndrome: Difference between revisions
Jump to navigation
Jump to search
(categ) |
|||
| Line 9: | Line 9: | ||
==[[Rufinamide]]== | ==[[Rufinamide]]== | ||
[http://www.ejpn-journal.com/article/S1090-3798(16)00004-0/abstract Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study] | [http://www.ejpn-journal.com/article/S1090-3798(16)00004-0/abstract Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study] | ||
==Clobazam== | |||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467745/pdf/tcrm-11-905.pdf Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndrome] | |||
{{disease|G40.7|Lennox-Gastaut syndrome}} | {{disease|G40.7|Lennox-Gastaut syndrome}} | ||
Revision as of 21:44, 31 January 2016
Lennox–Gastaut syndrome (LGS) is a difficult-to-treat form of childhood-onset epilepsy that most often appears between the second and sixth year of life. LGS is characterized by a triad of signs including frequent seizures of multiple types, an abnormal EEG pattern of less than 2.5 Hz slow spike wave activity,[1]
LGS children with a history of perinatal hypoxia or other perinatal event have earlier age of onset of seizures[2]
Links
Endoscopic epilepsy surgery: Emergence of a new procedure
Rufinamide
Clobazam
Disease classification WHO
G40.7 Lennox-Gastaut syndrome
